Orthopedic oncology accounts for a very small percentage in the field of orthopedics due to fact that the incidences of bone and soft tissue tumors are rare as compared to the benign tumors of musculoskeletal system which includes trauma, spine, hand and upper extremity, total joints and even pediatric orthopedics.

The report titled “Orthopedic Oncology Treatment Market - Growth, Share, Opportunities and Competitive Analysis, 2016–2023” offers strategic insights into the overall orthopedic oncology treatment market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of procedures and different geographical region. The procedures type segment studied for analyzing the overall orthopedic oncology treatment market are soft tissue excisions/resections, limb salvage surgery, amputation, adjuvant chemotherapy and reconstructive surgery. The reconstructive surgery held the largest share in the global orthopedic oncology market owing to the development in the prosthetics and bone grafting techniques that are being accepted by the patients. The limb salvage surgery is expected to grow at a subtle rate due to its cost effective nature. So will adjuvant chemotherapy segment would grow at steady rate.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in orthopedic oncology treatment market, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the orthopedic oncology treatment market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global orthopedic oncology treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global orthopedic oncology treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in orthopedic oncology treatment market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global orthopedic oncology treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.

Based on the type of procedures the global orthopedic oncology treatment market is segmented as follows:

• Soft Tissue Excisions/Resections
• Limb Salvage Surgery
• Amputation
• Adjuvant Chemotherapy
• Reconstructive Surgery
  • Hip & Joint Replacement
  • Bone Grafts

Orthopedic oncology accounts for a very small percentage in the field of orthopedics due to fact that the incidences of bone and soft tissue tumors are rare as compared to the benign tumors of musculoskeletal system which includes trauma, spine, hand and upper extremity, total joints and even pediatric orthopedics. However, the field of orthopedic oncology continues to be invigorated by exhilarating research and developments that has enhanced the level of treatment and care of patients with various bone and soft-tissue tumors. Currently, most patients with primary bone sarcomas are offered limb salvage surgery without increasing the risk of survival at the sarcoma centers. Moreover, the advances in the imaging technique and surgical techniques have further improved the treatment of patients with bone and soft-tissue malignancies. Orthopedic oncologists continue to collaborate with other subspecialists to integrate advances in surgical techniques. This is especially true for the development of implants and image guided surgery.

The global orthopedic oncology treatment market on type of procedures has been segmented into soft tissue excisions/resections, limb salvage surgery, amputation, adjuvant chemotherapy and reconstructive surgery. The reconstructive surgery is further sub-segmented into hip & joint replacement and bone grafts. The reconstructive surgery has the largest share in the global orthopedic oncology treatment market. The bone grafting techniques is anticipated to grow at the highest rate during the forecast period owing to the advances in the field of prosthesis and endoprosthesis.

For the purpose of this study, the global orthopedic oncology treatment market is categorized as follows:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA) 

For the purpose of this study, the global orthopedic oncology treatment market is categorized into regional markets viz., North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. In the base 2015, Asia Pacific was observed as the largest market for orthopedic oncology market. Large disease prevalence along with the growing healthcare ecosystem in the region has assisted the growth of the orthopedic oncology market in Asia-Pacific. Moreover, growth in the medical tourism in the region in the last decade has further fueled the market for orthopedic oncology treatment market in Asia-Pacific. Cancer incidence and mortality have been increasing in China, making cancer the leading cause of death since 2010 and a major public health problem in the country. In India, the incidence of bone cancer is 1/100 cancer cases, but it contributes to about 6-7% of pediatric cancer patients.  Latin America and Middle East and Africa are emerged as the most potential market due to the high prevalence of osteosarcoma and lower treatment option available in the region. Hence, these markets would exhibit a strong growth rate during the forecast period with the development in the healthcare infrastructure.